講演・口頭発表等 - 末永　光邦

21. Daisaku Kamiimabeppu, Takeru Wakatsuki, Daisuke Takahari, Naoki Fukuda, Hiroki Osumi, Izuma Nakayama, Mariko Ogura, Tarou Sato, Akira Ooki, Eiji Shinozaki, Mitsukuni Suenaga, Keisho Chin, Kensei Yamaguchi. Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC).. ASCO-GI 2020.01

22. Martin D. Berger, Shu Cao, Inti Zlobec, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Alessandro Lugli, Heinz-Josef Lenz. Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. ASCO annual meeting 2019.06

23. Fukuda Naoki, Takahari Daisuke, Suzuki Takeshi, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei. Ramucirumab+weekly nab-Paclitaxel併用療法で治療された胃癌患者の成績(Real world outcomes of gastric cancer patients treated with ramucirumab plus weekly nab-pactitaxel). 日本胃癌学会総会記事 2019.02.01

24. Ota Yumiko, Takahari Daisuke, Fukuda Naoki, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisyo, Yamaguchi Kensei. 進行胃癌に対するnivolumabの効果および予後因子(Outcome and prognostic factors of Nivotumab for advanced gastric cancer in our institution). 日本胃癌学会総会記事 2019.02.01

25. Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz. Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. ASCO Gastrointestinal Cancers Symposium 2019.01

26. Suenaga, M., Cao, S., Zhang, W., Matsusaka, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Schirripa, M., Barzi, A., Ueno, M., Lenz, H. J. . Role of enterocyte-specific gene polymorphisms in adjuvant treatment for stage III colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2019.01

27. Yukiko Izawa, Takashi Ichimura, Keisho Chin, Eiji Shinozaki, Daisuke Takahari, Mitsukuni Suenaga, Mariko Ogura, Takeru Wakatsuki, Hiroki Osumi, Izuma Nakayama, Shinji Mine, Naoki Hiki, Naoki Ishizuka, Kensei Yamaguchi. Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study).. ASCO-GI 2019.01

28. Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, Wakatsuki T, Ichimura T, Ogura M, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K.. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.. ASCO-GI 2019.01

29. M Suenaga, T Wakatsuki, M Ogura, T Ichimura, E Shinozaki, I Nakayama, H Osumi, Y Ota, K Chin, T Mashima, H Seimiya, D Takahari, K Yamaguchi.. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.. ESMO congress 2018.10

30. M. Berger, S. Stintzing, V. Heinemann, S. Cao, D. Yang, Y. Miyamoto, M. Suenaga, D.L. Hanna, S. Soni, A. Puccini, R. Tokunaga, M. Naseem, F. Battaglin, M. McSkane, W. Zhang, H.-J. Lenz. Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. ESMO congress 2018.10

31. H. Osumi, E. Shinozaki, H. Zembutsu, Y. Takeda, T. Wakatsuki, T. Ichimura, Y. Ota, I. Nakayama, M. Ogura, M. Suenaga, D. Takahari, K. Chin, A. Saiura, S. Takahashi, T. Noda, K. Yamaguch. Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis. ESMO congress 2018.10

32. R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi. p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan. ESMO congress 2018.10

33. Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kensei. 既治療のKRASエクソン2野生型大腸癌に対するサードライン療法としてのセツキシマブとイリノテカンの隔週治療の第II相試験(Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer). Cancer Science 2018.08.01

34. Suenaga, M., Schirripa, M., Loupakis, F., Cao, S., Zhang, W., Cremolini, C., Lonardi, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Soni, S., Barzi, A., Yamaguchi, T., Falcone, A., Lenz, H. J.. Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. 54th ASCO annual meeting 2018.06

35. 福田 直樹, 高張 大亮, 太田 弓子, 大隅 寛木, 中山 厳馬, 若槻 尊, 市村 崇, 小倉 真理子, 末永 光邦, 篠崎 英司, 陳 勁松, 山口 研成. 胃癌・肝転移のラムシルマブによる画像上形態学的変化の頻度・臨床的意義に関する検討(Morphologic change in gastric cancer patients with liver metastasis treated with ramucirumab). 日本胃癌学会総会記事 2018.03.01

36. Suenaga, M., Mashima, T., Kawata, N., Dan, S., Wakatsuki, T., Shinozaki, E., Ichimura, T., Ogura, M., takahari, D., Osumi, H., Ota, Y., Chin, K., Seimiya, H., Yamaguchi, K., Yamaguchi, T.. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation.. ASCO Gastrointestinal Cancers Symposium 2018.01

37. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Ning, Y., Bergamo, F., Zagonel, V., Rossini, D., Borelli, B., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Barzi, A., Yamaguchi, T., Loupakis, F., Lenz, H. J.. Matrix metalloproteinase-related gene polymorphisms predict efficacy of regorafenib in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2018.01

38. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Cremolini, C., Murgioni, S., Lonardi, S., Ning, Y., Okazaki, S., Berger, M. D., Miyamoto, Y., Gopez, R., Barzi, A., Loupakis, F., Falcone, A., Lenz, H.. Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. ASCO Gastrointestinal Cancers Symposium 2018.01

39. Yuta Ushida, Eiji Shinozaki, Keisho Chin, Mitsukuni Suenaga, Daisuke Takahari, Masato Ozaka, Mariko Ogura, Takashi Ichimura, Takeru Wakatsuki, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Yumiko Ota, Kensei Yamaguchi. Clinical outcomes of anti-EGFR antibody treatment for right-sided colon cancer patients without RAS, BRAF, and PIK3CA mutations in the later line.. ASCO-GI 2018.01

40. Tomoyuki Nagaoka, Eiji Shinozaki, Ryosuke Watanabe, Eiko Ueno, Yumiko Ota, Hiroki Osumi, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Mitsukuni Suenaga, Takashi Ichimura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi. Clinical significance of morphologic response and tumor shrinkage as predictive factors of Capeox+bevacizumab in 1st line treatment of metastatic colorectal cancer.. ASCO-GI 2018.01